ID

22136

Beschrijving

Study part: Day 0 EORTC. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Trefwoorden

Versies (2)

1. 20-05-17 20-05-17 -
2. 28-05-17 28-05-17 -

Houder van rechten

Roche

Geüploaded op

20 mei 2017

DOI

Voor een aanvraag inloggen.

Licentie